Alligator Bioscience AB (publ)

OM:ATORX Stock Report

Market Cap: SEK 413.9m

Alligator Bioscience Valuation

Is ATORX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATORX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATORX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATORX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATORX?

Key metric: As ATORX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ATORX. This is calculated by dividing ATORX's market cap by their current revenue.
What is ATORX's PS Ratio?
PS Ratio14.9x
SalesSEK 27.77m
Market CapSEK 413.89m

Price to Sales Ratio vs Peers

How does ATORX's PS Ratio compare to its peers?

The above table shows the PS ratio for ATORX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average24.9x
SANION Saniona
31.5x35.3%SEK 783.2m
SENZA SenzaGen
3.6x31.4%SEK 208.0m
IMMU Mendus
63.1x89.9%SEK 438.5m
XBRANE Xbrane Biopharma
1.4x61.1%SEK 276.2m
ATORX Alligator Bioscience
14.9x-8.0%SEK 413.9m

Price-To-Sales vs Peers: ATORX is good value based on its Price-To-Sales Ratio (14.9x) compared to the peer average (24.9x).

Price to Sales Ratio vs Industry

How does ATORX's PS Ratio compare vs other companies in the SE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.4x61.1%US$25.28m
SPRINT Sprint Bioscience
2.1x27.6%US$11.76m
PMDS PMD Device Solutions
0.9x62.0%US$3.11m
GEAN Genetic Analysis
1.3xn/aUS$2.32m
ATORX 14.9xIndustry Avg. 13.4xNo. of Companies8PS01224364860+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ATORX is expensive based on its Price-To-Sales Ratio (14.9x) compared to the Swedish Biotechs industry average (13.2x).

Price to Sales Ratio vs Fair Ratio

What is ATORX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATORX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.9x
Fair PS Ratio0.02x

Price-To-Sales vs Fair Ratio: ATORX is expensive based on its Price-To-Sales Ratio (14.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATORX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 0.55
SEK 2.00
+266.3%
25.0%SEK 2.50SEK 1.50n/a2
Nov ’25SEK 0.73
SEK 2.10
+186.1%
20.6%SEK 2.50SEK 1.50n/a3
Oct ’25SEK 1.29
SEK 2.27
+75.2%
9.1%SEK 2.50SEK 2.00n/a3
Sep ’25SEK 1.32
SEK 2.23
+69.2%
7.6%SEK 2.40SEK 2.00n/a3
Aug ’25SEK 1.43
SEK 2.23
+56.6%
7.6%SEK 2.40SEK 2.00n/a3
Jul ’25SEK 1.12
SEK 1.90
+70.3%
29.8%SEK 2.30SEK 1.10n/a3
Jun ’25SEK 1.08
SEK 1.90
+76.3%
29.8%SEK 2.30SEK 1.10n/a3
May ’25SEK 0.90
SEK 2.30
+155.6%
28.4%SEK 3.10SEK 1.50n/a3
Apr ’25SEK 0.99
SEK 2.30
+131.4%
28.4%SEK 3.10SEK 1.50n/a3
Mar ’25SEK 1.11
SEK 2.30
+107.2%
28.4%SEK 3.10SEK 1.50n/a3
Feb ’25SEK 1.24
SEK 1.83
+48.1%
32.2%SEK 2.30SEK 1.00n/a3
Jan ’25SEK 0.69
SEK 1.83
+166.1%
32.2%SEK 2.30SEK 1.00n/a3
Dec ’24SEK 0.49
SEK 1.83
+274.9%
32.2%SEK 2.30SEK 1.00n/a3
Nov ’24SEK 0.36
SEK 1.83
+408.6%
32.2%SEK 2.30SEK 1.00SEK 0.733
Oct ’24SEK 0.40
SEK 1.90
+372.0%
29.8%SEK 2.30SEK 1.10SEK 1.293
Sep ’24SEK 0.42
SEK 1.90
+347.1%
29.8%SEK 2.30SEK 1.10SEK 1.323
Aug ’24SEK 0.41
SEK 1.90
+366.8%
29.8%SEK 2.30SEK 1.10SEK 1.433
Jul ’24SEK 0.48
SEK 2.33
+390.2%
33.3%SEK 3.30SEK 1.40SEK 1.123
Jun ’24SEK 0.53
SEK 4.60
+766.3%
50.0%SEK 6.90SEK 2.30SEK 1.082
May ’24SEK 0.61
SEK 4.60
+654.1%
50.0%SEK 6.90SEK 2.30SEK 0.902
Apr ’24SEK 0.72
SEK 4.60
+536.2%
50.0%SEK 6.90SEK 2.30SEK 0.992
Mar ’24SEK 1.43
SEK 4.40
+206.8%
43.2%SEK 6.90SEK 2.30SEK 1.113
Feb ’24SEK 1.93
SEK 3.97
+105.3%
34.0%SEK 5.60SEK 2.30SEK 1.243
Jan ’24SEK 1.55
SEK 3.63
+134.4%
39.1%SEK 5.60SEK 2.30SEK 0.693
Dec ’23SEK 1.75
SEK 3.63
+107.6%
39.1%SEK 5.60SEK 2.30SEK 0.493
Nov ’23SEK 1.45
SEK 3.63
+150.9%
39.1%SEK 5.60SEK 2.30SEK 0.363

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

AstraZeneca

UK£164.2b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,472.00

7D

4.1%

1Y

9.8%

PMD Device Solutions

SEK 34.0m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.31

7D

2.3%

1Y

n/a

Corline Biomedical

SEK 132.0m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.14

7D

-7.0%

1Y

-54.0%